期刊文献+

BRAF V600E和TERT启动子突变与甲状腺乳头状癌临床病理特征的关系 被引量:11

BRAF V600E Mutation and TERT Promoter Mutation in Papillary Thyroid Carcinomas and Their Association with Clinicopathological Characteristics
原文传递
导出
摘要 目的探讨鼠类肉瘤滤过性毒菌致癌同源体B1(BRAF)V600E和端粒酶逆转录酶(TERT)启动子突变与甲状腺乳头状癌(PTC)临床病理特征之间的关系。方法采用聚合酶链式反应(PCR)直接测序检测326例PTC患者肿瘤组织的BRAF V600E和TERT启动子的突变情况,并分析其与临床病理特征之间的关系。结果 BRAFV600E突变率为82.52%(269/326),TERT启动子突变率为3.37%(11/326),其中C228T位点突变9例,C250T位点突变2例,BRAF V600E和TERT启动子同时突变者10例(3.07%)。单因素分析结果显示BRAF V600E基因突变与PTC患者年龄及是否肿瘤复发/远处转移有关(P<0.05),TERT启动子突变与患者年龄、肿瘤最大径、是否甲状腺腺外侵犯、T分期、AJCC分期及是否肿瘤复发/远处转移有关(P<0.05)。BRAF V600E和TERT启动子同时突变与患者年龄、肿瘤最大径、是否甲状腺腺外侵犯、T分期及AJCC分期有关(P<0.05)。结论 PTC患者肿瘤组织BRAF V600E和TERT启动子同时突变时提示肿瘤侵袭性高。 Objective To explore the relationships of BRAF V600 E and TERT promoter mutations with the clinicopathological features in papillary thyroid carcinoma(PTC). Methods The mutations of BRAF V600 E and TERT promoters were examined by PCR-direct sequencing in tumor tissues from 326 PTC patients, while the relationships between the gene mutations and clinicopathological features were analyzed. Results BRAF V600 E mutation was found in 269/326(82.52%), and TERT promoter mutation in 11/326(3.37%) of PTC patients. In site mutations of TERT promoter, 9 cases were C228 T and 2 cases were C250 T. Single factor analysis showed that BRAF V600 E mutations were significantly associated with age and recurrence/distant metastasis of tumor(P<0.05),while TERT promoter mutations were significantly associated with age, tumor size, extrathyroidal extension, T stage, AJCC stage and recurrence/distant metastasis of tumor(P<0.05). Coexistence of BRAF V600 E and TERT promoter mutations(BRAF^+/TERT^+) were particularly associated with age, tumor size, extrathyroidal extension, T stage and AJCC stage(P<0.05). Conclusion Coexistence of BRAF V600 E and TERT promoter mutations in PTC shows more aggressive tumor behavior.
作者 杨钿 陈昶 潘南方 孙林雍 江小林 李金男 唐源 姜勇 YANG Tian;CHEN Chang;PAN Nan-fang;SUN Lin-yong;JIANG Xiao-lin;LI Jin-nan;TANG Yuan;JIANG Yong(Department of Pathology,West China Hospital,Sichuan University,Chengdu 610041,China;West China School of Medicine,Sichuan University,Chengdu 610041,China)
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2019年第6期919-924,共6页 Journal of Sichuan University(Medical Sciences)
基金 四川省科技厅项目(No.2018HH0037) 四川大学“大学生创新创业训练计划”(No.C 2019104717)资助
关键词 甲状腺乳头状癌 BRAF V600E突变 TERT启动子突变 临床病理特征 Papillary thyroid carcinomas BRAF V600E mutation TERT promoter mutations Clinicopathological characteristics
  • 相关文献

参考文献1

二级参考文献18

  • 1Ries LAG. Melbert D. Krapcho M. et al. SEER Cancer Statistics Review. 1975-2005. Bethesda. MD: National Cancer Institute. 2007 :907. 被引量:1
  • 2Schlumberger M. Pacini F. Prognostic factors. In: Thyroid Tumors. Paris: Nucleon Editions. 2003: 111-125. 被引量:1
  • 3Witt RL. Initial surgical management of thyroid cancer. Surg On col Clin N Am.2008; 17(1): 71-9l. 被引量:1
  • 4Davies H. Bignell GR. Cox C. et al. Mutations of the BRAF gene in human cancer. Nature.2002;417(6892) :949-954. 被引量:1
  • 5DeLuca AM. Srinivas A. Alani RM. BRAF kinase in melanoma development and progression. Expert Rev Mol Med , 2008;100) :3-6. 被引量:1
  • 6Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005; 12( 2) : 245-262. 被引量:1
  • 7Kebebew E. Weng J. Bauer J. et al. The prevalence and prognostic value of BRF mutation in thyroid cancer. Ann Surg , 2007; 246 (3) : 466-470. 被引量:1
  • 8Kim TH. Park YJ. Lim J A. et al. The association of the BRAF ( V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer,2012;118(7):1764-1773. 被引量:1
  • 9Xing M. Clark D. Guan H. et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol , 2009;27(18):2977-2982. 被引量:1
  • 10Costa AM. Herrero A. Fresno MF. et al. BRF mutation associated with other genetic events identifes a subset of aggressive papillary thyroid carcinoma. Clin Endocrino\, 2008; 68(4) :618-634. 被引量:1

共引文献14

同被引文献68

引证文献11

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部